Navigation Links
PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL
Date:5/30/2008

n, affecting less than 200,000 individuals in the United States.(1)

Eltrombopag is an investigational, once-daily oral treatment developed to induce the production of cells in the bone marrow to increase platelets, which are critical in minimizing the incidence of bleeding in chronic ITP.

Eltrombopag, a novel oral thrombopoeitin (TPO) receptor agonist, if approved, would be the first oral short-term treatment of previously treated patients with chronic ITP to increase platelet counts and reduce or prevent bleeding.

In the pivotal studies, the most common adverse events observed in patients taking eltrombopag were headache, nasopharyngitis, and nausea.

About the data

The NDA submission is supported by the largest database of clinical trial information on investigational therapies for chronic ITP patients. Two pivotal trials (one Phase III trial and one Phase II trial), were submitted to support the filing.

About ITP

Chronic ITP is a disorder marked by increased platelet destruction and/or inadequate platelet production in the blood, which causes an increased risk of bruising and bleeding.(2,3) There are estimated to be approximately 60,000 individuals diagnosed with chronic ITP in the U.S.(4) People with chronic ITP often bleed from small blood vessels causing bruises, nosebleeds or even fatal gastrointestinal or intra cerebral bleeds, although these are rare.(3)

About Eltrombopag

Eltrombopag is an oral, non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals (Nasdaq:

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
9. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
10. Prime Therapeutics Receives TIPPS Certification
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Dallas, TX (PRWEB) November 22, 2014 ... Society (ICS) as the complaint that the individual ... times for voiding. The report “Nocturia – Pipeline ... therapeutic development for Nocturia, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
(Date:11/22/2014)... York, New York (PRWEB) November 22, 2014 ... of power morcellators ( http://www.morcellatorlawsuit2015.com ) in minimally-invasive ... 450 new signatures since the end of October, Bernstein ... had signed the petition as of November 21st, 2014. ... 31st, when 86,042 supporters had signed on to the ...
(Date:11/22/2014)... wide variety and complexity of foods served at holiday ... allergies, an expert warns. "Every person is different ... that it can be really difficult to avoid all ... allergy and clinical immunology at Wake Forest Baptist Medical ... you know you have food allergies, caution should overrule ...
(Date:11/22/2014)... York, New York (PRWEB) November 22, 2014 ... filed on behalf of patients who allegedly developed Type ... forward in the federal multidistrict litigation now underway in ... LLP reports. According to court documents, the litigation will ... 10:00 a.m. The Court has directed Lead Counsel for ...
(Date:11/22/2014)... Hastings and Hastings, a discount accident attorney in ... with the option of leaving an online review using ... and easy to navigate website that has recently been ... allows clients to research the Hastings and Hastings law ... when retaining an attorney. Those who have been injured ...
Breaking Medicine News(10 mins):Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3
... treatment for women that cuts off blood flow to ... appropriate treatment for women in a Clinical Therapeutics article ... England Journal of Medicine . "UFE (also called ... and minimally invasive option for women to consider. This ...
... , SAN FRANCISCO, Aug. 13 Nile Therapeutics, ... of novel therapeutics for heart failure patients, today announced its second quarter ... , , For the second quarter of 2009, ... share, compared to a net loss of approximately $3.8 million, or $0.16 ...
... , , DENVER, Aug. ... BDMS ) , operators of PERFECT TEETH ... and six months ended June 30, 2009. For the quarter ended ... 2.0%, to $15.2 million. Net revenue increased $93,000, or 1.1%, to ...
... areas of the brain needed to perceive feelings, study ... drinking can affect the ability to recognize other people,s ... used functional MRI to monitor brain activity in 15 ... faces with positive or negative emotional expressions. The brain ...
... , GUANGZHOU, China, Aug. 13 ... Medicine" or "the Company"), a developer,and a leading distributor ... (TCM), nutritional and dietary supplements, and,medical devices and medical ... Second Quarter 2009 Highlights:, ...
... , New England Journal of Medicine Highlights ... Decrease Hysterectomy Rate in United States , , ... invasive interventional radiology treatment for women that cuts off blood flow ... treatment for women in a Clinical Therapeutics article in the Aug. ...
Cached Medicine News:Health News:Interventional radiology treatment for uterine fibroids: Safe, nonsurgical option 2Health News:Interventional radiology treatment for uterine fibroids: Safe, nonsurgical option 3Health News:Nile Therapeutics Reports 2009 Second Quarter Financial Results 2Health News:Nile Therapeutics Reports 2009 Second Quarter Financial Results 3Health News:Nile Therapeutics Reports 2009 Second Quarter Financial Results 4Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 2Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 3Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 4Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 5Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 6Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 7Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 8Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 9Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 10Health News:Boozing Blunts Ability to Read Faces 2Health News:China Medicine Announces Second Quarter 2009 Results 2Health News:China Medicine Announces Second Quarter 2009 Results 3Health News:China Medicine Announces Second Quarter 2009 Results 4Health News:China Medicine Announces Second Quarter 2009 Results 5Health News:China Medicine Announces Second Quarter 2009 Results 6Health News:China Medicine Announces Second Quarter 2009 Results 7Health News:China Medicine Announces Second Quarter 2009 Results 8Health News:China Medicine Announces Second Quarter 2009 Results 9Health News:China Medicine Announces Second Quarter 2009 Results 10Health News:China Medicine Announces Second Quarter 2009 Results 11Health News:China Medicine Announces Second Quarter 2009 Results 12Health News:China Medicine Announces Second Quarter 2009 Results 13Health News:China Medicine Announces Second Quarter 2009 Results 14Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 2Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 3Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 4Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 5
(Date:11/21/2014)... Nov. 21, 2014 Clementia ... Medicines Agency (EMA) has granted Orphan Medicinal ... product candidate, for the treatment of fibrodysplasia ... severely disabling genetic disease characterized by painful, ... and new abnormal bone formation. This process, ...
(Date:11/21/2014)... IRVINE, Calif. , Nov. 20, 2014  Edwards ... leader in the science of heart valves and hemodynamic ... corporate giving in 2014 to support a strong launch ... Heartbeat Matters , and to improve the global communities ... In 2014, Edwards, global corporate giving will exceed $8 ...
(Date:11/21/2014)... /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) announced today ... be presenting at the 26 th Annual Piper Jaffray ... New York . The formal presentation is scheduled ... addition, Mr. Krakauer and Jorgen B. Hansen , President ... the day. An audio webcast will be ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... the best of both worlds, the ... is the latest addition to the ... bipolar cautery instruments for ophthalmic surgery. ... extrusion aspiration and backflush functionality in ...
...
...
Medicine Products: